This test has not been FDA cleared or approved.

Positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes. The test should not be used to diagnose acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. Negative results do not preclude acute SARS-CoV-2 infection.

Individuals may have detectable virus present for several weeks following seroconversion. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. Results are for the detection of SARS-CoV-2 antibodies. SARS-CoV-2 (COVID-19) IgG antibody serology test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Manage your communication preferences or unsubscribe. All third-party marks-® and ™-are the property of their respective owners. Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. Terms of Use | Privacy Policy | Contact Us | This communication is intended for healthcare professionals in the USA. Practice-Advisory-Cervical-Cancer-Screening-Update. Practice Advisory: Cervical Cancer Screening (Update). American College of Obstetricians and Gynecologists.Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Kaufman HW, Alagia DP, Chen Z, Onisko A, Austin RM.

Download questdiagnostics com